SCHOLAR ROCK HLDG DL-,001 Logo
US80706P1030
A2JMQW
SRRK

SCHOLAR ROCK HLDG DL-,001

Prognose

Analytikernes gennemsnitlige kursmål er 64,98 € (+48,09 %). Medianen er 64,71 € (+47,47 %).

Køb
  13
Behold
  2
Sælg
  0

Diskussioner i communityet

Der er endnu ingen diskussion om dette aktiv.

Start diskussion

  • Scholar Rock clarifies FDA requirements for ISEMBYLD, shares fall sharply

    Scholar Rock confirmed that the FDA requires post‑marketing conditions for ISEMBYLD, including a study on safety in pregnancy and 15‑day adverse‑event reporting for bone fractures. Management had previously (and incorrectly) stated that no such conditions existed. The stock then fell 6.4% to $51.85 and declined 9.7% on the week. Scholar Rock said it will carry out the requested studies and reporting in line with FDA requirements; analysts subsequently adjusted ratings and price targets. » Mere på de.investing.com


  • FDA grants approval for ISEMBYLD; Scholar Rock stock rises

    The FDA approved ISEMBYLD (apitegromab-mstn) as the first muscle-specific treatment for spinal muscular atrophy in adults and children aged two and older who are already receiving an SMN2-directed therapy. The news pushed Scholar Rock’s stock up about 9% pre-market to $60.45 and converts the company into a commercial biopharma company. Several analysts sharply raised price targets and reiterated buy ratings; apitegromab is projected to generate billions in sales by 2035. Scholar Rock reports roughly $492 million in cash and has independent fill-and-finish and manufacturing capabilities for the product launch. » Mere på de.investing.com


  • Scholar Rock receives FDA approval for Isembyld to treat SMA

    The FDA has approved Isembyld (Apitegromab‑mstn) for the treatment of spinal muscular atrophy in patients aged two and older. The approval is based on the phase‑3 SAPPHIRE study, in which patients receiving Isembyld in addition to standard therapy showed a significant improvement on the Hammersmith scale after one year; 34.2% achieved an increase of at least three points versus 13.5% with placebo. The US commercial launch has begun, the stock climbed more than 14% to an all‑time high, and Scholar Rock is shifting from a clinical biotech company to a commercial drugmaker. » Mere på deraktionaer.de


  • Scholar Rock prepares for FDA decision on apitegromab

    Weeks before the PDUFA date on September 30, 2026, Scholar Rock highlights late Phase III data on apitegromab as well as secured commercial production and go‑to‑market infrastructure. After an earlier Complete Response Letter over manufacturing issues, the company moved commercial fill‑finish production to an alternative site and says it has already produced commercial vials there. Management emphasizes statistically significant Phase III results, high treatment adherence, and prepared sales, nursing and patient‑support structures for the US, with plans for Europe and Japan. » Mere på de.investing.com


  • Scholar Rock nears approval for apitegromab

    At the Cantor Fitzgerald Global Healthcare Conference, Scholar Rock said the FDA has identified compliance with manufacturing requirements as the only remaining approval hurdle and that the company has since established a contractually committed alternative fill-and-finish facility. The crucial PDUFA date is September 30, 2026; management is holding intensive talks with the FDA about labeling and safety data. Scholar Rock has roughly $500 million in cash, sees worldwide market potential in the billions, and expects initial but manageable reimbursement and market-access hurdles during the first three to five quarters after launch. » Mere på de.investing.com

Virksomhedstal

I det seneste kvartal havde SCHOLAR ROCK HLDG DL-,001 en omsætning på 503,22 t € og et nettoresultat på -94,68 mio. €

(EUR) september 2026
YoY
Omsætning 503,22 t -
Bruttofortjeneste 496,16 t 101,15 %
Nettoresultat -94,68 mio. 8,69 %
EBITDA -90,36 mio. 5,55 %

Fundamentale data

Nøgletal Værdi
Markedsværdi
5,35 mia. €
Antal aktier
122 mio.
Højeste/laveste i 52 uger
56,28 € - 35,26 €
Udbytte Nej
Beta
0,62
P/E (PE Ratio)
-14,95
PEG (PEG Ratio)
28,66
K/I (PB Ratio)
37,77
P/S (PS Ratio)
10.301,85

Virksomhedsprofil

Scholar Rock Holding Corporation er et biofarmaceutisk selskab, der fokuserer på opdagelse og udvikling af lægemidler til behandling af alvorlige sygdomme, hvor signalering via proteinvækstfaktorer spiller en grundlæggende rolle. Selskabet udvikler Apitegromab, en hæmmer af aktiveringen af latent myostatin, som har gennemført fase 3-kliniske forsøg til behandling af spinal muskelatrofi; og SRK-181, som er i fase 1-kliniske forsøg til behandling af kræftformer, der er resistente over for checkpoint-hæmmerbehandlinger, såsom anti-PD-1- eller anti-PD-L1-antistofbehandlinger. Selskabet udvikler desuden en portefølje af nye produktkandidater med potentiale til at forandre livet for patienter, der lider af en række alvorlige sygdomme, herunder neuromuskulære lidelser, kræft og fibrose. Selskabet har en samarbejdsaftale med Gilead Sciences, Inc. om at opdage og udvikle specifikke hæmmere af aktivering af transformerende vækstfaktor beta til behandling af fibrotiske sygdomme. Scholar Rock Holding Corporation blev grundlagt i 2012 og har hovedkvarter i Cambridge, Massachusetts.

Navn
SCHOLAR ROCK HLDG DL-,001
CEO
David L. Hallal
Hjemsted Cambridge, ma
USA
Websted
Sektor
Dagligvarer
Branche
Fødevarer
Børsnotering
25.05.2018
Medarbejdere 289

Tickersymboler

Børs Symbol
NASDAQ
SRRK
Frankfurt
2QK.F
Düsseldorf
2QK.DU
München
2QK.MU
🍪

Parqet  bruger cookies. Læs mere